| Article ID | Journal | Published Year | Pages | File Type | 
|---|---|---|---|---|
| 2839590 | Clínica e Investigación en Arteriosclerosis | 2013 | 6 Pages | 
Abstract
												Statins are the current basis of lipid-lowering therapy, despite which may have limitations on efficacy and safety. In high risk patients who do not achieve current lipid goals, in those intolerant to statins or those with atherogenic dyslipidemia, it is possible combine two or more lipid lowering drugs, including statins, ezetimibe, bile acid sequestrants, fibrates, niacin and prescription omega-3 fatty acids. However, for most of these combination therapies pivotal data on clinical outcomes are still lacking.
											Related Topics
												
													Life Sciences
													Biochemistry, Genetics and Molecular Biology
													Physiology
												
											Authors
												Ovidio Muñiz Grijalvo, Jose Villar Ortiz, 
											